| Dr Alexandra Dezii, DO | |
|
14023 Southwest Fwy, Sugar Land, TX 77478-3550 | |
| (281) 325-4100 | |
| (281) 325-4292 |
| Full Name | Dr Alexandra Dezii |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Location | 14023 Southwest Fwy, Sugar Land, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225691926 | NPI | - | NPPES |
| Entity Name | Memorial Hermann Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003985102 PECOS PAC ID: 7012008360 Enrollment ID: O20070801000368 |
News Archive
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the United States Food and Drug Administration (FDA) granted orphan designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients experience a progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic being developed to increase muscle mass and strength.
Cancer that has spread, or metastasized, from its original site to other tissues and organs in the body is a leading cause of cancer death.
The final results of a six-month, multi-center, open-label Phase 3 study of VIAject® (more-rapid-acting injectable human insulin) versus regular human insulin (RHI) in 471 patients with type 2 diabetes were presented today by Helena Rodbard, M.D., at the 70th Scientific Sessions of the American Diabetes Association. Dr. Rodbard was a principal investigator of this study, which was designed to evaluate the safety and efficacy of VIAject® versus regular human insulin when used in combination with insulin glargine.
Neurelis, Inc. today announced that the United States Food and Drug Administration (FDA) has cleared an Investigational New Drug application (IND) to commence clinical trials advancing the development of NRL-1 for the treatment of acute breakthrough seizures.
Tampa General Hospital is the first hospital in Hillsborough County – and one of only three in the Tampa Bay area – to earn the Baby-Friendly hospital designation from Baby-Friendly USA, Inc. for its commitment to supporting breastfeeding mothers and their babies.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Alexandra Dezii, DO 7600 Beechnut St, Houston, TX 77074-4302 Ph: (713) 456-5000 | Dr Alexandra Dezii, DO 14023 Southwest Fwy, Sugar Land, TX 77478-3550 Ph: (281) 325-4100 |
News Archive
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced the United States Food and Drug Administration (FDA) granted orphan designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients experience a progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic being developed to increase muscle mass and strength.
Cancer that has spread, or metastasized, from its original site to other tissues and organs in the body is a leading cause of cancer death.
The final results of a six-month, multi-center, open-label Phase 3 study of VIAject® (more-rapid-acting injectable human insulin) versus regular human insulin (RHI) in 471 patients with type 2 diabetes were presented today by Helena Rodbard, M.D., at the 70th Scientific Sessions of the American Diabetes Association. Dr. Rodbard was a principal investigator of this study, which was designed to evaluate the safety and efficacy of VIAject® versus regular human insulin when used in combination with insulin glargine.
Neurelis, Inc. today announced that the United States Food and Drug Administration (FDA) has cleared an Investigational New Drug application (IND) to commence clinical trials advancing the development of NRL-1 for the treatment of acute breakthrough seizures.
Tampa General Hospital is the first hospital in Hillsborough County – and one of only three in the Tampa Bay area – to earn the Baby-Friendly hospital designation from Baby-Friendly USA, Inc. for its commitment to supporting breastfeeding mothers and their babies.
› Verified 9 days ago
Dr. Vickas Dangayach, M.D.,MBA Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 16811 Southwest Fwy Fl 3, Sugar Land, TX 77479 Phone: 281-276-0836 Fax: 281-275-0760 | |
Ms. Mahpara Bushra Khaliq, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 16811 Southwest Fwy Ste 300, Sugar Land, TX 77479 Phone: 281-276-0836 | |
Samir Joglekar, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 16605 Southwest Fwy, Suite 175, Sugar Land, TX 77479 Phone: 713-777-5334 Fax: 713-429-5207 | |
Naveen Sajja, M.D Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 16655 Southwest Fwy, Sugar Land, TX 77479 Phone: 281-274-7000 | |
Sidrah Sheikh, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 16655 Southwest Fwy, Sugar Land, TX 77479 Phone: 281-276-0836 Fax: 281-276-8544 | |
Salman S. Aly, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 6903 Brisbane Ct Ste 100, Sugar Land, TX 77479 Phone: 832-886-4774 | |
Dr. Aaliya Islam Amer, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 6514 Highway 90a Ste 100, Sugar Land, TX 77498 Phone: 281-313-0100 Fax: 281-699-2151 |